Insomnia is a common problem with a point prevalence between 10 and 30% of adult patients.  Rates of insomnia have increased in recent years, representing 46.2 million of the adult US population.

​

Insomnia can be an acute problem that is related to medication side effects, trauma/anxiety, travel, etc., but it is frequently chronic. Psychological stress, which leads to a lack of sleep, results in reduced epidermal barrier function. Sleeping less than 5 hours a night has been linked to more inherent aging.  

It is more problematic as we advance in age, and many of the existing sleep aides have adverse side effects and can be habit-forming. Recent studies have explored CBD as a potential treatment for insomnia. Current data is unclear whether improvements in sleep quality are a primary effect of CBD or if improvements are due to the impact that CBD has on pain and anxiety (both of which have an adverse effect on sleep). 

​

The habit-forming nature of many existing sedative-hypnotics, such as benzodiazepines, was a consideration in SOTA formula development. SOTA Sleep was formulated to produce a sleep aid that is free from the dangers of many of the available hypnotics. Our SIP methodology validated proven sleep ingredients, including GABA, melatonin, and peppermint, all of which activate for faster sleep relief via water-soluble CBD.